Firas El Chaer, MD

PRIMARY APPOINTMENT:
Associate Professor, Medicine: Hematology and Oncology

CONTACT:
UVA Division of Hematology/Oncology
PO Box 800716
Charlottesville, VA 22908
Telephone: 434-982-6811
Fax: 434-244-7534

• Primary Education:University of Balamand
• Residency:Englewood Hospital and Medical Center
• Fellowship:University of Maryland
• Fellowship:Baylor College of Medicine

Dr. El Chaer’s research interests focus on improving the outcomes for acute leukemia in adults by focusing on targeted therapies and overcoming resistance mechanisms, measurable residual disease, and novel therapies for myeloproliferative neoplasm.

• Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia.
  Dillon LW, Gui G, Ravindra N, Andrew G, Mukherjee D, Wong ZC, Huang Y, Gerhold J, Holman M, D’Angelo J, Miller J, Higgins J, Salk JJ, Auletta JJ, El Chaer F, Devine SM, Jimenez-Jimenez AM, De Lima MJG, Litzow MR, Kebriaei P, Saber W, Spellman SR, Zeger SL, Page KM, Hourigan CS.JAMA Oncol. 2024 Aug 1;10(8):1104-1110. doi: 10.1001/jamaoncol.2024.0985.PMID: 38696205
• American Society of Transplantation and Cellular Therapy Series: #7 – Management of Respiratory Syncytial Virus Infections in Hematopoietic Cell Transplant Recipients.
  El Chaer F, Kaul DR, Englund JA, Boeckh M, Batista MV, Seo SK, Carpenter PA, Navarro D, Hirsch HH, Ison MG, Papanicolaou GA, Chemaly RF.Transplant Cell Ther. 2023 Dec;29(12):730-738. doi: 10.1016/j.jtct.2023.09.018. Epub 2023 Sep 30.PMID: 37783338
• Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts.
  Shallis RM, Daver N, Altman JK, Komrokji RS, Pollyea DA, Badar T, Bewersdorf JP, Bhatt VR, de Botton S, de la Fuente Burguera A, Carraway HE, Desai P, Dillon R, Duployez N, El Chaer F, Fathi AT, Freeman SD, Gojo I, Grunwald MR, Jonas BA, Konopleva M, Lin TL, Mannis GN, Mascarenhas J, Michaelis LC, Mims AS, Montesinos P, Pozdnyakova O, Pratz KW, Schuh AC, Sekeres MA, Smith CC, Stahl M, Subklewe M, Uy GL, Voso MT, Walter RB, Wang ES, Zeidner JF, Žučenka A, Zeidan AM.Lancet Haematol. 2023 Sep;10(9):e767-e776. doi: 10.1016/S2352-3026(23)00159-X. Epub 2023 Aug 9.PMID: 37572683
• DNA Sequencing to Detect Residual Disease in Adults With Acute Myeloid Leukemia Prior to Hematopoietic Cell Transplant.
  Dillon LW, Gui G, Page KM, Ravindra N, Wong ZC, Andrew G, Mukherjee D, Zeger SL, El Chaer F, Spellman S, Howard A, Chen K, Auletta J, Devine SM, Jimenez Jimenez AM, De Lima MJG, Litzow MR, Kebriaei P, Saber W, Weisdorf DJ, Hourigan CS.JAMA. 2023 Mar 7;329(9):745-755. doi: 10.1001/jama.2023.1363.PMID: 36881031
• How I treat AML incorporating the updated classifications and guidelines.
  El Chaer F, Hourigan CS, Zeidan AM.Blood. 2023 Jun 8;141(23):2813-2823. doi: 10.1182/blood.2022017808.PMID: 36758209
• How I treat and prevent COVID-19 in patients with hematologic malignancies and recipients of cellular therapies.
  El Chaer F, Auletta JJ, Chemaly RF.Blood. 2022 Aug 18;140(7):673-684. doi: 10.1182/blood.2022016089.PMID: 35776899
• How I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipients.
  El Chaer F, Shah DP, Chemaly RF.Blood. 2016 Dec 8;128(23):2624-2636. doi: 10.1182/blood-2016-06-688432. Epub 2016 Oct 19.PMID: 27760756

• A Phase 1, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients withIntermediate-2 or High-Risk Primary or Secondary Myelofibrosis
  Study Contact: Avani Hopkins
• Palliative Care Oncology in Relapsed, Refractory, and High-Risk Leukemia Patients: Randomized Phase II Study
  Study Contact: Katherine Murphy